Press Releases

2023-09-14

FUJIFILM Diosynth Biotechnologies Announces New Darlington, UK Viral Vector Gene Therapy Facility is cGMP Ready for Manufacturing

2023-08-24

FUJIFILM Diosynth Biotechnologies Announces New Strategic, Customer-Focused Business Structure

2023-06-29

Fujifilm Appoints Lars Petersen as President & CEO of FUJIFILM Diosynth Biotechnologies, leading Global Bio CDMO

2023-06-07

Fujifilm to Enhance Commercial Presence in Asia for Biologics and Advanced Therapies Contract Services

2023-04-19

FUJIFILM Diosynth Biotechnologies Acquires Additional 41 Acres of Land in RTP 

2022-11-15

FUJIFILM Diosynth Biotechnologies Expands Strategic Partnership with NC State

to create future innovation opportunities through new research projects, sustainable facility design, and bioprocessing advancements at the future Holly Springs cell culture biomanufacturing site

2022-10-27

FUJIFILM Diosynth Biotechnologies enters into an Agreement with Argenx to Manufacture Efgartigimod, a Monoclonal Antibody (mAb) for the Treatment of Severe Autoimmune Diseases

Today announced an agreement with argenx to manufacture efgartigimod, a monoclonal antibody (mAb) fragment to target the neonatal Fc receptor (FcRn), in patients with severe autoimmune disease.

2022-10-25

FUJIFILM Diosynth Biotechnologies Held Groundbreaking Celebration for Expansion of its Single-Use Manufacturing Campus in Texas

$300-million expansion will make this the largest single-use CDMO production campus in North America

2022-10-24

FUJIFILM Diosynth Biotechnologies and RoosterBio Announce Collaboration to enable GMP Manufacturing of Cell and Exosome Therapies

Strategic collaboration with RoosterBio, Inc. , a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services. Through this collaboration, FUJIFILM Diosynth Biotechnologies will incorporate RoosterBio’s industry leading process development technology for both MSC and…

2022-09-22

FUJIFILM Diosynth Biotechnologies Breaks Ground on Large-Scale Microbial Manufacturing Facility Expansion in Billingham, UK

FUJIFILM Diosynth Biotechnologies announced today the start of the expansion of its large-scale microbial manufacturing facility located at the Billingham, UK campus.

2022-09-12

FUJIFILM Diosynth Biotechnologies breaks ground on a USD 1.6 billion (11 billion Danish kroner) expansion in Hillerød, Denmark

Groundbreaking ceremony held today to celebrate the start of its new expansion project to transform the Denmark site into the largest end-to-end CDMO in Europe.

2022-06-29

Fujifilm to invest USD 1.6 billion to enhance and expand its global offering of cell culture manufacturing services

This investment will enhance FUJIFILM Diosynth Biotechnologies’ sites in Hillerød, Denmark, and Texas in the United States.

2022-04-26

FUJIFILM Diosynth Biotechnologies Breaks Ground on Expansion of its BioProcess Innovation Center

FDB held a groundbreaking ceremony for the expansion of its BioProcess Innovation Center in Research Triangle Park (RTP) on April 21, 2022. 

2022-04-12

Chimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates

Philadelphia, PA and College Station, TX – April 12, 2022 ‒ Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, today announced it has entered into a manufacturing agreement…

2022-04-04

Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.

Facility acquisition includes 134 employees in manufacturing and quality positions

2022-03-17

FUJIFILM Diosynth Biotechnologies Gifts $200,000 to Wake Tech Foundation to Establish Early College Suite

FDB announces a $200,000 contribution to the Wake Tech Foundation to establish the FUJIFILM Diosynth Biotechnologies Early College Suite.

2022-01-26

Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.

FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. Located in Thousand Oaks, California,…

2022-01-05

FUJIFILM Diosynth Biotechnologies Doubles its Existing Laboratory Footprint in North Carolina

Expands the sites’ Process Development, Process Characterization and Analytical Services and adds approximately 145 skilled positions by 2024.

2021-12-14

FUJIFILM Diosynth Biotechnologies to Increase Advanced Therapy and Vaccine Production Capacity with New $300 Million Facility in Texas

The Texas site is the largest single-use CDMO production campus in North America Adds approximately 150 skilled positions to the site by 2024 and is supported by the State of Texas through a $1.5 million Enterprise Fund Award

2021-12-02

FUJIFILM Diosynth Biotechnologies confirms £400 million investment plans to create the largest multi-modal biopharmaceutical manufacturing site in the United Kingdom

The expansion is expected to create up to 350 highly-skilled jobs on Teesside.

2021-10-26

Istari Oncology Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its Viral Immunotherapy PVSRIPO

College Station, TX and Durham, NC – October 26, 2021 ‒ FUJIFILM Diosynth Biotechnologies (FDB) and Istari Oncology today announced that they have entered into an agreement for the manufacturing of Istari Oncology’s viral immunotherapy, PVSRIPO, currently being investigated for…

2021-10-14

FUJIFILM DIOSYNTH BIOTECHNOLOGIES BREAKS GROUND ON THE LARGEST CELL CULTURE BIOPHARMACEUTICAL CDMO FACILITY IN NORTH AMERICA

The new, state-of-the-art facility will be located in Holly Springs, North Carolina

2021-06-29

$850 Million USD (¥90 Billion Yen) investment in FUJIFILM Diosynth Biotechnologies to add additional development and manufacturing capacity

The investments will be made to increase capacity for biologics including recombinant vaccines for COVID-19 and advanced gene therapies in the United Kingdom and the United States

2021-04-01

FUJIFILM DIOSYNTH BIOTECHNOLOGIES BREAKS GROUND FOR EXPANSION OF ITS MICROBIAL PRODUCTION FACILITY IN THE UNITED KINGDOM

Virtual groundbreaking ceremony celebrates the start of expansion that will triple microbial production capacity

2021-03-18

Fujifilm Selects North Carolina as the Location to Build the Largest Cell Culture Biopharmaceutical CDMO Facility in North America

Fujifilm to invest $2 Billion and create 725 jobs with its new  state-of-the-art large-scale cell culture manufacturing facility in Holly Springs, North Carolina

2021-03-03

FUJIFILM DIOSYNTH BIOTECHNOLOGIES BREAKS GROUND FOR MAJOR EXPANSION OF ITS LARGE SCALE BIOLOGICS PRODUCTION FACILITY IN DENMARK

Virtual ground-breaking ceremony celebrates initiation of expansion to double cell culture capacity and add large scale fill/finish capabilities

2021-02-13

FUJIFILM Diosynth Biotechnologies Welcomes UK Prime Minister Boris Johnson to UK COVID-19 Vaccine Manufacturing Site

FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors, welcomed UK Prime Minister Boris Johnson to Teesside at its Billingham site, on Saturday 13 February to meet the team working…

2021-01-14

Fujifilm and the Center for Advanced Biological Innovation and Manufacturing Announce $76M in Funding for Manufacturing and Innovation Center

FUJIFILM Corporation (COO: Kenji Sukeno) and the Center for Advanced Biological Innovation and Manufacturing (CABIM), today announced that it has secured $76 million in financing and signed a lease for a 40,000 square-foot site in Watertown, Massachusetts at The Arsenal…

2021-01-11

FUJIFILM Diosynth Biotechnologies Begins Production of Two COVID-19 Vaccines Candidates at Texas Facility

Texas A&M System contract designates FUJIFILM Diosynth Biotechnologies facility for emergency federal use

2021-01-07

Fujifilm to Invest Over 200 Billion yen (2 Billion USD) to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.

End-to-End Single-Site Solution from Drug Substances to Fill-Finish & Packaging

2021-01-04

Fujifilm to invest $40 Million to Establish a New State-of-the-Art Viral Vector and Advanced Therapy Process Development and Manufacturing Facility

Establishing a presence in Massachusetts within the academia and pharma communities to perform cutting-edge research and innovation in the field of advanced therapies.

2021-01-04

STEVE BAGSHAW, NON-EXECUTIVE CHAIRMAN OF FUJIFILM DIOSYNTH BIOTECHNOLOGIES RECOGNIZED IN NEW YEAR’S HONORS LIST 2021

Billingham, United Kingdom, January 4, 2021 – FUJIFILM Diosynth Biotechnologies, is pleased to share that Steve Bagshaw, non-executive chairman of FUJIFILM Diosynth Biotechnologies, has been awarded Commander of the Most Excellent Order of the British Empire (CBE) for Services to…

2020-12-16

FUJIFILM DIOSYNTH BIOTECHNOLOGIES EXPANDS ITS PROCESS CHARACTERIZATION OFFERING

Today FUJIFILM Diosynth Biotechnologies announced the news about expanding its global process characterization offering with the addition of dedicated laboratories in the North East of the United Kingdom by late fall 2021. This will double our existing process characterization capacity.

2020-10-08

FUJIFILM Diosynth Biotechnologies Stands Ready to Manufacture Lilly COVID-19 Antibody for Low- and Middle-Income Countries

FUJIFILM Diosynth Biotechnologies today announced that it will manufacture Eli Lilly and Company’s COVID-19 therapeutic antibody at its GMP facility in Hillerød, Denmark, deploying capacity reserved for the COVID-19 Therapeutics Accelerator.

2020-10-07

FUJIFILM TO EXPAND ITS VIRAL VECTOR CDMO SERVICES TO THE UK

FUJIFILM Corporation is expanding its gene therapy offering with the addition of viral vector process development and GMP manufacturing services at FUJIFILM Diosynth Biotechnologies in the North East of the United Kingdom (UK).

2020-08-19

FUJIFILM DIOSYNTH BIOTECHNOLOGIES BREAKS GROUND FOR ADVANCED THERAPIES INNOVATION CENTER IN TEXAS

Virtual ground-breaking ceremony held as planned expansion work begins COLLEGE STATION, Texas, August 19, 2020 – FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies,, held a virtual ground-breaking ceremony…

2020-08-14

Novavax and UK Government Announce Collaboration and Purchase Agreement for Novavax’ COVID-19 Vaccine Candidate

UK Government to purchase 60 million doses of NVX-CoV2373. Novavax to partner with FUJIFILM Diosynth Biotechnologies to manufacture antigen component of NVX-CoV2373 in UK. Novavax and UK government to collaborate on Phase 3 clinical trial in U.K commencing in 3rd…

2020-07-27

FUJIFILM Diosynth Biotechnologies Texas Facility to Support COVID-19 Vaccine Candidate Manufacturing

FUJIFILM Diosynth Biotechnologies, announced today that its College Station, Texas, site will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed.

2020-07-23

NOVAVAX AND FUJIFILM DIOSYNTH BIOTECHNOLOGIES INITIATE LARGE SCALE MANUFACTURING OF COVID-19 VACCINE CANDIDATE

Novavax, Inc. and FUJIFILM Diosynth Biotechnologies announced today an agreement to manufacture bulk drug substance for Novavax’ COVID-19 vaccine candidate.

2020-06-09

FUJIFILM TO INVEST 100 BILLION YEN (928 MILLION USD) TO EXPAND ITS LARGE SCALE BIOLOGICS PRODUCTION FACILITY IN DENMARK

-Doubling the drug substance production capacity -Establishing end-to-end capabilities in one site, including drug substance manufacturing, fill/finish, assembly, labeling and packaging

2020-04-30

FUJIFILM Diosynth Biotechnologies teams with COVID-19 Therapeutics Accelerator to reserve manufacturing capacity and provide technical expertise to deliver future COVID-19 therapies

HILLERØD, Denmark, April 30, 2020 – FUJIFILM Diosynth Biotechnologies, a world leading biologics-Contract Development and Manufacturing Organization (CDMO), today announced that it will reserve manufacturing…

2020-04-23

FUJIFILM Diosynth Biotechnologies Enters Strategic Partnership With OXGENE™ To Address Supply Bottlenecks In Gene Therapy Development And Manufacturing

Capabilities expand to supplying plasmids for triple transfections

2020-03-18

Fujifilm Invests $83M USD to Expand FUJIFILM Diosynth Biotechnologies Microbial Capacity

TOKYO, March 18, 2020 — FUJIFILM Corporation announced today that it will invest approximately 9 billion yen ($83M USD) to expand the microbial production capacity of FUJIFILM Diosynth Biotechnologies (FDB).

2020-03-16

Christine Vannais is appointed as FDB’s North Carolina Site Chief Operating Officer

Christine joined FDB in 2012 and she has led the North Carolina Manufacturing Operations team since 2014 as part of the Site Leadership Team.

2020-03-12

FDB commences construction of planned UK BioCampus expansion

FDB commences construction of planned UK BioCampus expansion.

2020-02-28

FUJIFILM Diosynth Biotechnologies expands its Gene Therapy Manufacturing Capacity

Capacity increase will support production of high throughput and large volume gene therapy products.

2020-02-25

FUJIFILM Diosynth Biotechnologies expands North Carolina Facility

FUJIFILM Diosynth Biotechnologies expands North Carolina Facility

2019-12-03

FUJIFILM Diosynth Biotechnologies Named A Top Ten Healthiest Employer Nationally

FUJIFILM Diosynth Biotechnologies Named A Top Ten Healthiest Employer Nationally

2019-11-25

FUJIFILM Diosynth Biotechnologies is Founding Member of the New Center of Innovation and Manufacturing in Boston, MA

FUJIFILM Diosynth Biotechnologies (FDB), a leading global biologics and gene therapy Contract Development and Manufacturing Organization (CDMO) has announced its participation as a founding member in a newly announced center for innovation and manufacturing of next-generation medicines.

2019-11-14

FUJIFILM DIOSYNTH BIOTECHNOLOGIES ANNOUNCES $55 MILLION USD INVESTMENT TO EXPAND GENE THERAPY DEVELOPMENT CAPABILITIES

FUJIFILM Diosynth Biotechnologies will be expanding its gene therapy process and analytical development capabilities with the addition of new dedicated laboratories

2019-11-04

Top Honors in TBJ’s 2019 HEALTHIEST EMPLOYER

FUJIFILM DIOSYNTH BIOTECHNOLOGIES NAMED A 2019 HEALTHIEST EMPLOYER

2019-08-01

FUJIFILM Completes Acquisition of Biogen’s Manufacturing Site in Denmark

Fujifilm Completes Acquisition of Biogen’s Manufacturing Site in Denmark Tokyo, August 1, 2019 ‒ FUJIFILM Corporation (“Fujifilm”) today announced that it has completed the acquisition…

2019-06-06

FUJIFILM introduces a Novel, Fully Integrated Continuous Production System

TOKYO, June 5, 2019 /PRNewswire/ — FUJIFILM Corporation (President: Kenji Sukeno), today announced an initial $10M USD investment to establish a full scale, fully integrated continuous processing facility for non-GMP manufacture…

2019-04-30

FUJIFILM Announces Expansion Of Its Cell Culture Process Development Labs

FUJIFILM DIOSYNTH BIOTECHNOLOGIES ANNOUNCES EXPANSION OF ITS CELL CULTURE PROCESS DEVELOPMENT LABS AND THE CREATION OF A NEW BIOCAMPUS AS PART OF EXPANSION TO ITS…

2019-04-11

Fujifilm Introduces A 10 Week Cell Line Development Timeline, Apollo™ X

FUJIFILM ANNOUNCES THE INTRODUCTION OF A 10 WEEK CELL LINE DEVELOPMENT TIMELINE WITH ITS APOLLO™ X ADVANCED MAMMALIAN EXPRESSION SYSTEM The timeline maintains a robust…

2019-03-12

Fujifilm To Acquire Large-Scale Biologics Manufacturing Site From Biogen

FUJIFILM Corporation today announced that it has entered into an agreement to acquire Biogen (Denmark) Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark from Biogen for approximately US$890 million in cash.

2019-01-31

FUJIFILM ANNOUNCES THE CREATION OF A STRATEGIC PARTNERSHIP PROGRAM TO FURTHER DEVELOP ITS CAPABILITIES IN BIOPROCESSING

Billingham, UK, January 31, 2019 ‒ FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture…

2019-01-15

FUJIFILM announces the extension of its Fill Finish services to include recombinant protein aseptic filling market.

FUJIFILM Corporation (President: Kenji Sukeno, Fujifilm), has announced the extension of its Fill/Finish services to include cGMP aseptic filling of recombinant proteins. These services will…

2019-01-10

FUJIFILM Launches Next Generation APOLLO™ X Advanced Mammalian Expression System

FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies,…

2019-01-07

FUJIFILM to Invest 10 Billion Yen in its BIO CDMO Business

FUJIFILM Corporation (President: Kenji Sukeno) announced plans to invest approximately JPY 10 billion (approximately $90 million U.S. dollars) in order to expand its Bio Contract…

2018-12-07

Announcement of Co-Chair Role for CEO, Steve Bagshaw

FUJIFILM Diosynth Biotechnologies Announces Co-Chair Role Of Its CEO, Steve Bagshaw, In The Preparation Of The United Kingdom’s Bioeconomy Growth Strategy

2018-11-01

FUJIFILM Announces AMECRYS Collaboration Reaches Project Milestone

FUJIFILM announces that AMECRYS Collaboration reaches project milestone to develop new technologies to improve Downstream Processing of Monoclonal Antibodies

2018-07-27

Fill Finish Service Expansion to Gene Therapy & Viral Vaccine

Announcement of the extension of its gene therapy and viral vaccine Fill/Finish capabilities to provide services in support of late phase candidates and commercial supply….

2018-05-31

Opening of Cambridge Collaboration Center in Cambridge, MA

At BIO 2018 FUJIFILM announces the opening of Cambridge Collaboration Center to expand its footprint

2018-01-24

New Flexible Manufacturing Facility Opens

FUJIFILM ANNOUNCES THE OPENING OF ITS FLEXIBLE MANUFACTURING FACILITY FOR THE PRODUCTION OF CLINICAL AND COMMERCIAL GENE THERAPIES FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract…

2018-01-18

cGMP Readiness of Saturn™ mAb Facilities

FUJIFILM Corporation (President: Kenji Sukeno) today announced the on-time completion of Qualification activities, enabling commencement of cGMP operations for its Saturn™ mAb manufacturing facilities at FUJIFILM Diosynth Biotechnologies (“FDB”), a world leading cGMP Contract Development and Manufacturing Organization in College…

2018-01-03

Biotech Showcase 2018 Presentation

FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), is pleased to announce that Martin Meeson, President and COO of FUJIFILM Diosynth Biotechnologies U.S.A., is scheduled to present at EBD’s Biotech Showcase 2018 event during the…

2017-11-21

Bagshaw Awarded N.E. Business Executive of the Year

FUJIFILM Diosynth Biotechnologies, a leading global Contract Development and Manufacturing Organization (CDMO), is pleased to announce that its Chief Executive Officer, Steve Bagshaw, has been awarded “North East Business Executive of the Year 2017”; a prestigious award organized by The…

2017-11-06

CDMO Business Expansion

FUJIFILM Corporation (President: Kenji Sukeno) is to invest a total of 3.2billion yen on its CDMO* sites in the U.S.A. and the U.K. in order to accelerate the expansion of the company’s business for developing and manufacturing biopharmaceuticals** under contract…

2017-09-12

FUJIFILM Diosynth Biotechnologies Opens Cell Culture Process Development Laboratories

FUJIFILM Diosynth Biotechnologies has announced its opening of the 10,000 square foot, state-of-the-art cell culture Process Development Laboratories in Wilton Centre, Teesside. These laboratories were realized through a JPY1 billion ($9M USD) investment which is part of the greater JPY14…

2017-06-20

Completion of 100th pAVEway Program

FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), has announced the successful completion of its 100th program using its pAVEway™ Advanced Protein Expression system which was introduced to the market during the BIO 2007 convention…

2017-04-18

New Process Development Facility Investment

FUJIFILM Corporation (President: Kenji Sukeno) will increase production capacity by investing about JPY14 billion ($130m) in the USA and UK in order to expand the…

2017-03-01

Saturn mAb Platform™ to Support cGMP Manufacturing

FUJIFILM Diosynth Biotechnologies, has announced the expansion of its Monoclonal Antibody development and manufacturing services with the introduction of its Saturn mAb Platform™. Read the…

2017-02-28

New Bio CDMO Division

FUJIFILM Launches Bio CDMO Division to Expand cGMP Contract Development and Manufacturing Operations Aiming to achieve 100 billion yen in revenue by FY2024/March READ MORE

2016-06-06

New Microbial Biologics Facility

Fujifilm Diosynth Announces Collaboration on a New 20,000-Liter Microbial Biologics Facility for use by its Contract Development and Manufacturing Customers Billingham, U.K.,  June 6, 2016…

2016-05-09

New Laboratory Facility – Research Triangle Park, NC

FUJIFILM Diosynth Biotechnologies Opens New Laboratory Facility in Research Triangle Park, NC MORRISVILLE, N.C., May 9, 2016 – FUJIFILM Diosynth Biotechnologies U.S.A., Inc., a Biologics…

2016-05-05

Phase I Clinical Trial of Anti-Cancer Agent

Department taps Centers for Innovation in Advanced Development and Manufacturing

2015-01-13

Laboratory Facility in Research Triangle Park, NC

Fujifilm Diosynth Biotechnologies breaks ground on laboratory facility in Research Triangle Park, NC MORRISVILLE, N.C., January 13, 2015 – FUJIFILM Diosynth Biotechnologies U.S.A., Inc., a…

2014-12-31

New Years’ Honours List

MBE for Fujifilm Diosynth Biotechnologies’ Subhash Chaudhary in new years’ honours list Billingham : 31st December 2014 : FUJIFILM Diosynth Biotechnologies is delighted to announce…

2014-12-18

Fujifilm completes acquisition of Kalon Biotherapeutics

Fujifilm completes acquisition of Kalon Biotherapeutics Morrisville, North Carolina and College Station, Texas – December 18, 2014. FUJIFILM Diosynth Biotechnologies U.S.A. Inc. (FDBU), a FUJIFILM…

2014-10-09

‘Apollo™’ mammalian expression platform

Fujifilm Diosynth Biotechnologies announces the launch of its ‘Apollo™’ mammalian expression platform Billingham, Teesside, UK and Research Triangle Park, NC, USA, 9th October 2014 :…

2014-09-16

Fujifilm chooses ambr250 mini bioreactor system

Fujifilm chooses ambr250 mini bioreactor system to optimise its fermentation process development TAP Biosystems (now part of the Sartorius Stedim Biotech Group), a leading supplier…

2014-08-24

Significant Improvement of SYN-004

Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile Rockville, MD, August 28,…

2014-08-19

Two New 2,000L Single-use Bioreactors

FUJIFILM Diosynth Biotechnologies expands cell culture manufacturing capacity with addition of two new 2,000L single-use bioreactors Billingham, Teesside, UK and Research Triangle Park, NC, USA,…

2014-06-23

Expansion of R&D Facilities

FUJIFILM Disoynth Biotechnologies continues Expansion of R&D Facilities including addition of Latest High Throughput Equipment Fujifilm Diosynth Biotechnologies has announced continued expansion of its process development…

2013-10-09

FUJIFILM receives MHRA

FUJIFILM Diosynth Biotechnologies’ UK site receives MHRA Manufacturing License FUJIFILM Diosynth Biotechnologies has announced that it has received a renewal of its Manufacturer’s Licence from…

2013-10-02

New Manufacturing Facility

FUJIFILM Diosynth Biotechnologies’ Opens New Manufacturing Facility FUJIFILM Diosynth Biotechnologies today formally opened its new mammalian cell culture cGMP manufacturing facility at a ceremony performed…

2013-07-18

Evaluating Synthetic Biologics’ SYN-004

FUJIFILM Diosynth Biotechnologies to Evaluate of Synthetic Biologics’ Propietary Beta-Lactamase Enzyme, SYN-004 Rockville, MD, July 18, 2013 – Synthetic Biologics, Inc. (NYSE MKT: SYN), a…

2013-04-22

New Cell Banking Facility at Billingham, UK Site

FUJFILM Diosynth Biotechnologies commissions new cell banking facility at Billingham, UK Site FUJIFILM Diosynth Biotechnologies has announced that it has commissioned on time its new…

2012-10-24

FUJIFILM Diosynth Biotechnologies Announces Strategic Alliance

FUJIFILM Diosynth Biotechnologies Announces Strategic Alliance with Piramal Healthcare for Production of Antibody Drug Conjugates FUJIFILM Diosynth Biotechnologies has announced it has entered into a…

2012-03-23

FUJIFILM expands R&D Capabilities

FUJIFILM Diosynth Biotechnologies expands R&D Capabilities at its Billingham, UK Site FUJIFILM Diosynth Biotechnologies has completed the first phase of a 3m ($4.5m) investment in…

2011-10-25

Collaboration for Novel Anti-Staph Biologic

FUJIFILM Diosynth Biotechnologies and ContraFect Corporation Announce Development and Manufacturing Collaboration for Novel Anti-Staph Biologic FUJIFILM Diosynth Biotechnologies and ContraFect Corporation announced today that they…

2011-06-01

FUJIFILM Expands Mammalian Cell Culture Capacity

FUJIFILM Diosynth Biotechnologies Expands Mammalian Cell Culture Capacity FUJIFILM Diosynth Biotechnologies is expanding its existing contract manufacturing capabilities with the addition of a 1,000L Xcellerex…

2011-04-01

FUJIFILM Completes Acquisition of Merck

FUJIFILM Completes Acquisition of Merck Biomanufacturing Network FUJIFILM Diosynth Biotechnologies has been announced as the new name for the former Merck BioManufacturing Network (known as…

2011-02-28

FUJIFILM to Acquire Merck

FUJIFILM to Acquire Merck Biomanufacturing Network TOKYO and WHITEHOUSE STATION, NJ., February 28, 2011 – FUJIFILM Corporation and Merck (NYSE:MRK), known as MSD outside the United…

2010-09-30

MSD Signs Deal with ThromboGenics

MSD Signs Deal with ThromboGenics for Long-term Commercial Supply of Microplasmin Leuven, Belgium – 30 September, 2010 – ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company…